{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:07:56Z","timestamp":1790809676873,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01595-8","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:08:50Z","timestamp":1790762930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1633-3827","authenticated-orcid":false,"given":"Ahmed","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8218-481X","authenticated-orcid":false,"given":"Maria","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4871-6595","authenticated-orcid":false,"given":"Faiza","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0732-9413","authenticated-orcid":false,"given":"Muhammad","family":"Saffi Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ansab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4163-0013","authenticated-orcid":false,"given":"Zain","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navkirat","family":"Kahlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1595_CR1","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/CANCERS16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer. Epidemiology, risk factors, and prevention. Cancers. 2024;16:1530. https:\/\/doi.org\/10.3390\/CANCERS16081530","journal-title":"Cancers"},{"key":"1595_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/JAMA.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA - J Am Med Association. 2021;325:669\u201385. https:\/\/doi.org\/10.1001\/JAMA.2021.0106.","journal-title":"JAMA - J Am Med Association"},{"key":"1595_CR3","doi-asserted-by":"publisher","unstructured":"Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall\u2019Olio FG et al. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. https:\/\/doi.org\/10.3748\/WJG.V22.I2.519","DOI":"10.3748\/WJG.V22.I2.519"},{"key":"1595_CR4","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.3390\/PHARMACEUTICS15112620","volume":"15","author":"AS Adebayo","year":"2023","unstructured":"Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. Colorectal cancer: disease process, current treatment options, and future perspectives. Pharmaceutics. 2023;15:2620. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15112620","journal-title":"Pharmaceutics"},{"key":"1595_CR5","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nat 2013. 2013;501:7467. https:\/\/doi.org\/10.1038\/nature12625.","journal-title":"Nat 2013"},{"key":"1595_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/NATURE12627","volume":"501","author":"PL Bedard","year":"2013","unstructured":"Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501:355\u201364. https:\/\/doi.org\/10.1038\/NATURE12627.","journal-title":"Nature"},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clcc.2017.03.012","volume":"16","author":"F Leal","year":"2017","unstructured":"Leal F, Ferreira FP, Sasse AD. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2017;16:405\u2013e4092. https:\/\/doi.org\/10.1016\/j.clcc.2017.03.012.","journal-title":"Clin Colorectal Cancer"},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1634\/THEONCOLOGIST.2009-0317","volume":"15","author":"F Kazazi-Hyseni","year":"2010","unstructured":"Kazazi-Hyseni F, Beijnen JH, Schellens JHM, Bevacizumab. Oncologist. 2010;15:819\u201325. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2009-0317.","journal-title":"Oncologist"},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med. 2007;357:2040\u20138. https:\/\/doi.org\/10.1056\/NEJMoa071834.","journal-title":"N Engl J Med"},{"key":"1595_CR10","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2013.31.15_SUPPL.3517","volume":"31","author":"A Passardi","year":"2013","unstructured":"Passardi A, Scarpi E, Cavanna L, Fontana A, Vertogen B, Ruscelli S, et al. Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial. J Clin Oncol. 2013;31:3517\u20133517. https:\/\/doi.org\/10.1200\/JCO.2013.31.15_SUPPL.3517.","journal-title":"J Clin Oncol"},{"key":"1595_CR11","first-page":"334","volume":"8","author":"Y Lv","year":"2015","unstructured":"Lv Y, Yang Z, Zhao L, Zhao S, Han J, Zheng L. The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. Int J Clin Exp Med. 2015;8:334.","journal-title":"Int J Clin Exp Med"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"11741","DOI":"10.1007\/S13277-014-2227-Z","volume":"35","author":"Z Lv","year":"2014","unstructured":"Lv ZC, Ning JY, Chen HB. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. Tumor Biology. 2014;35:11741\u201350. https:\/\/doi.org\/10.1007\/S13277-014-2227-Z","journal-title":"Tumor Biology"},{"key":"1595_CR13","doi-asserted-by":"publisher","first-page":"527053","DOI":"10.3389\/FONC.2020.00868","volume":"10","author":"R Li","year":"2020","unstructured":"Li R, Liang M, Liang X, Yang L, Su M, Lai KP. Chemotherapeutic effectiveness of combining cetuximab for metastatic colorectal cancer treatment: A system review and meta-analysis. Front Oncol. 2020;10:527053. https:\/\/doi.org\/10.3389\/FONC.2020.00868.","journal-title":"Front Oncol"},{"key":"1595_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/BMJ.N71.","DOI":"10.1136\/BMJ.N71"},{"key":"1595_CR15","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/BMJ.L4898.","DOI":"10.1136\/BMJ.L4898"},{"key":"1595_CR16","unstructured":"Study Details. | Cetuximab\/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT01802645?term=NCT01802645.&rank=1. (Accessed 16 Jun 2025)."},{"key":"1595_CR17","doi-asserted-by":"publisher","first-page":"10217","DOI":"10.1038\/s41467-024-54460-2","volume":"15","author":"M Shiozawa","year":"2024","unstructured":"Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, et al. Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial. Nat Commun. 2024;15:10217. https:\/\/doi.org\/10.1038\/s41467-024-54460-2.","journal-title":"Nat Commun"},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.22.01420","volume":"41","author":"S Stintzing","year":"2023","unstructured":"Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol. 2023;41:4143\u201353. https:\/\/doi.org\/10.1200\/JCO.22.01420.","journal-title":"J Clin Oncol"},{"key":"1595_CR19","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1200\/JCO.2020.38.15_suppl.4024","volume":"38","author":"G Folprecht","year":"2020","unstructured":"Folprecht G, Mende M, Liersch T, Bechstein WO, Kohne C-H, Stein A, et al. Cetuximab\/irinotecan\/5-FU +\/-oxaliplatin or FOLFOXIRI +\/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study). J Clin Oncol. 2020;38:4024\u20134024. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4024.","journal-title":"J Clin Oncol"},{"key":"1595_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.18632\/oncotarget.26626","volume":"10","author":"T Ogata","year":"2019","unstructured":"Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, et al. Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. Oncotarget. 2019;10:1070\u201384. https:\/\/doi.org\/10.18632\/oncotarget.26626.","journal-title":"Oncotarget"},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4.","journal-title":"Lancet Oncol"},{"key":"1595_CR22","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/JAMA.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017;317:2392\u2013401. https:\/\/doi.org\/10.1001\/JAMA.2017.7105.","journal-title":"JAMA"},{"key":"1595_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, De Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663\u201371. https:\/\/doi.org\/10.1200\/JCO.2008.20.8397.","journal-title":"J Clin Oncol"},{"key":"1595_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9.","journal-title":"Lancet Oncol"},{"key":"1595_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMOA1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab\u2013FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369:1023\u201334. https:\/\/doi.org\/10.1056\/NEJMOA1305275.","journal-title":"N Engl J Med"},{"key":"1595_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)00150-9.","journal-title":"Lancet Oncol"},{"key":"1595_CR27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMOA0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med. 2009;360:1408\u201317. https:\/\/doi.org\/10.1056\/NEJMOA0805019.","journal-title":"N Engl J Med"},{"key":"1595_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer. 2015;51:587\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2015.01.054.","journal-title":"Eur J Cancer"},{"key":"1595_CR29","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMOA032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004;350:2335\u201342. https:\/\/doi.org\/10.1056\/NEJMOA032691.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01595-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:53:13Z","timestamp":1790808793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01595-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01595-8","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review and meta-analysis of previously published data and does not involve any new studies with human participants or animals performed by the authors. Therefore, ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of the manuscript have no relevant financial or non-financial conflicts of interest to disclose.","order":2,"name":"Ethics","label":"Compliance With the Ethical Standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"231"}}